Previous studies on ephrin-A1 in NSCLC have been conflicting, as associations to improved patient outcome have been reported [2,23], while upregulation of the ephrin-A1 receptor EphA2 has also been related to poor clinical outcomes in many types of cancer [2]. This evidence concerns the gene EFNA1 and cancer.